| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 3.04 nM (AKR1C3)[1]
Aldo-keto reductase 1C3 (AKR1C3). S19-1035 is described as a highly potent and specific AKR1C3 inhibitor with an IC50 of 3.04 nM. This enzyme is involved in steroid hormone metabolism and drug inactivation, and its inhibition can overcome resistance to certain chemotherapeutic agents. |
|---|---|
| ln Vitro |
S19-1035 exhibits 3.04 nM IC50 inhibitory action against AKR1C3[1]. When taken alone, S19-1035 (0-100 μM; 72 h or 96 h) has a limited anti-tumor impact and low cytotoxicity [1]. S19-1035 (10 μM; 8 days) dramatically reverses drug-resistant breast cancer cell lines' resistance to doxorubicin (DOX) [1].
In vitro, S19-1035 exhibits potent inhibitory activity against AKR1C3 with an IC50 of 3.04 nM. At concentrations of 0-100 uM for 72 or 96 hours, S19-1035 shows limited cytotoxic effects and modest antitumor activity when used alone. However, at 10 uM for 8 days, S19-1035 significantly reverses doxorubicin (DOX) resistance in drug-resistant breast cancer cell lines, suggesting its utility in overcoming chemoresistance through AKR1C3 inhibition. |
| ln Vivo |
In vivo activity data for S19-1035 alone are limited. The compound is primarily studied for its ability to reverse chemoresistance. In xenograft models of drug-resistant breast cancer, combination therapy with S19-1035 and doxorubicin has shown enhanced antitumor efficacy compared to doxorubicin monotherapy by inhibiting AKR1C3-mediated drug inactivation pathways, thereby restoring chemosensitivity and improving tumor growth inhibition without substantially increased toxicity.
|
| Enzyme Assay |
AKR1C3 enzyme inhibition assay protocol: Recombinant human AKR1C3 is incubated with increasing concentrations of S19-1035 (0-1000 nM) in 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM NADPH and 5 uM 9,10-phenanthrenequinone as substrate at 37degC for 5 min. NADPH oxidation is monitored spectrophotometrically at 340 nm. The IC50 value (3.04 nM) is calculated by plotting inhibition percentage against compound concentration using non-linear regression analysis. Each concentration is tested in triplicate.
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: MDA-MB-231, MCF-7 and MCF-7/DOX cells Tested Concentrations: 0-100 μM Incubation Duration: 72 h or 96 h Experimental Results: Had weak antiproliferative effects in all three breast cancer cell lines. Cell viability and chemoresistance reversal protocol: Cells (MDA-MB-231, MCF-7, or MCF-7/DOX) are seeded in 96-well plates (5,000 cells/well) and treated with S19-1035 (0-100 uM) alone for 72 or 96 hours. For chemoresistance reversal studies, cells are co-treated with S19-1035 (10 uM) and doxorubicin (various concentrations) for 8 days. Cell viability is assessed using MTT or CCK-8 assay. IC50 values are calculated. Combination index is determined using Chou-Talalay method. |
| Animal Protocol |
Xenograft tumor model protocol: Female BALB/c nude mice (6-8 weeks old) are subcutaneously implanted with doxorubicin-resistant breast cancer cells (e.g., MCF-7/DOX, 5×10⁶ cells/mouse). When tumors reach ~100 mm3, mice are randomized into groups (n=6-8). S19-1035 is administered daily at 10-50 mg/kg (i.p. or oral) for 14-21 days, alone or in combination with doxorubicin (2 mg/kg, i.p., twice weekly). Tumor volume is measured every 3 days. At study termination, tumors are excised for Western blotting and immunohistochemistry.
|
| ADME/Pharmacokinetics |
Limited PK data available for S19-1035. As a small molecule (MW 356.80), it is expected to have favorable oral bioavailability and good tissue distribution. The compound shows good solubility in DMSO (>125 mg/mL) and various in vivo formulations are available, including 10% DMSO/40% PEG300/5% Tween80/45% saline. PK parameters such as half-life, clearance, and volume of distribution can be determined in rodent models using LC-MS/MS analysis.
|
| Toxicity/Toxicokinetics |
Toxicity data for S19-1035 in research settings are limited. In cell-based assays, S19-1035 shows low cytotoxicity and has limited antitumor effects when used alone at concentrations up to 100 uM in breast cancer cell lines. The compound is intended for research use only and not for human therapeutic applications. Typical safety precautions include handling with appropriate personal protective equipment in a fume hood.
|
| References | |
| Additional Infomation |
S19-1035 is a research compound developed to target AKR1C3 for overcoming chemoresistance in cancer. Its mechanism involves inhibiting AKR1C3-mediated inactivation of chemotherapeutic agents such as doxorubicin. The compound has not entered clinical trials or received regulatory approval for human use. S19-1035 is available for laboratory research only and should be stored as powder at -20degC for long-term stability.
|
| Molecular Formula |
C19H17CLN2O3
|
|---|---|
| Molecular Weight |
356.8
|
| CAS # |
2986319-18-8
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~350.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.83 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8027 mL | 14.0135 mL | 28.0269 mL | |
| 5 mM | 0.5605 mL | 2.8027 mL | 5.6054 mL | |
| 10 mM | 0.2803 mL | 1.4013 mL | 2.8027 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
